Anika Therapeutics Inc.

ANIK Healthcare Drug Manufacturers Specialty & Generic

Anika Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $112.8 million, down 5.91% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 189.3% and free cash flow grew 61.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

19.98 0.71 −3.43%
Market cap
$276.9M
P/E
0.0×
Fwd P/E
−20.0×
Dividend yield
—
F-score
6/9
Altman Z
3.13
Beneish M
−2.84
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Cash and Short Term Investments
124.76 157.26 159.01 184.94 98.32 94.39 86.33 68.74 55.63 57.48
Receivables
27.60 23.83 20.78 23.08 24.10 29.84 34.63 26.36 23.59 23.69
Inventory
15.98 22.04 21.30 22.00 46.21 36.01 39.77 24.43 23.81 18.79
Other current assets
2.10 3.21 1.85 4.29 8.75 8.29 8.83 36.31 5.13 —
Total current assets
170.44 206.33 202.94 234.31 177.38 168.53 169.55 163.31 113.65 103.36
Property, Plant, Equpment (Net)
52.30 56.18 54.11 50.78 50.61 47.60 48.28 37.45 38.99 40.32
Long-term receivables
— — — — — — — — 5.94 5.64
Goodwill and Intangible Assets (Total)
17.44 18.85 17.04 15.28 99.57 90.16 81.94 10.15 9.62 9.70
Long Term Assets (Tax, Deferred)
— — — — — — 1.45 1.49 1.18 1.28
Long-term assets (Other)
0.07 1.25 4.90 7.48 15.42 20.29 17.22 30.69 7.68 4.03
Total non-current assets
69.81 76.29 76.05 96.40 188.22 179.01 179.58 107.32 89.09 86.91
Total Assets
240.25 282.62 278.99 330.71 365.61 347.54 349.13 270.63 202.74 190.27
Accounts Payable
2.30 6.75 3.14 3.83 8.98 7.63 9.07 6.19 5.62 6.04
Accrued Expenses
6.50 6.33 8.15 12.45 14.79 17.85 18.84 14.07 13.57 15.87
Other current liabilities
6.50 6.33 7.76 11.30 13.09 4.32 15.96 10.80 4.12 —
Total current liabilities
8.80 13.07 11.29 16.28 36.87 29.80 27.91 31.06 23.31 21.91
Long Term Tax Liability (Deferred)
6.55 5.39 3.54 4.33 11.90 10.16 6.44 — — —
Non-current Liabilities (Other)
2.13 0.66 0.55 0.36 23.56 1.26 0.40 1.39 1.43 0.70
Total non-current liabilities
8.67 6.05 4.09 26.06 56.34 30.66 35.65 27.31 25.45 24.90
Total liabilities
17.47 19.13 15.38 42.33 93.21 60.45 63.57 58.37 48.75 46.81
Additional Paid In Capital
61.74 68.62 50.76 48.71 55.36 67.08 81.14 90.01 88.96 87.50
Common Stock (Net)
0.15 0.15 0.14 0.14 0.14 0.14 0.15 0.15 0.14 0.14
Retained Earnings
168.21 199.51 218.23 245.43 221.44 225.58 210.72 128.05 71.67 60.79
Common Equity (Total)
222.77 263.49 263.61 288.38 272.40 287.09 285.56 212.27 153.99 143.47
Shareholders Equity (Total)
222.77 263.49 263.61 288.38 272.40 287.09 285.56 212.27 153.99 143.47
Shareholders Equity and Liabilities (Total)
240.25 282.62 278.99 330.71 365.61 347.54 349.13 270.63 202.74 190.27
Shares (Common)
14.63 14.69 14.20 14.31 14.33 14.44 14.63 14.66 14.42 13.89
Shareholders Equity (Tangible)
205.33 244.64 246.57 273.10 172.83 196.92 203.63 202.12 144.37 133.76
Net Debt
(124.76) (157.26) (159.01) (184.94) (98.32) (94.39) (86.33) (68.74) (55.63) (57.48)
Total Debt
— — — 22.51 22.46 20.95 30.89 — — —

Fold the line items

In millions of $ except per-share values · columns are period end dates